#### **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

March 8, 2022 Date of Report (date of earliest event reported)

### **Momentus Inc.**

(Exact name of registrant as specified in its charter)

Delaware

001-39128 (Commission File Number)

84-1905538 (I.R.S. Employer Identification No.)

(State or other jurisdiction of incorporation or organization) 3901 N. First Street San Jose, California

(Address of Principal Executive Offices)

95134

(Zip Code)

(650) 564-7820 Registrant's telephone number, including area code

Stable Road Acquisition Corp.

1345 Abbot Kinney Blvd. Venice, California 2020 90291

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to section 12(g) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered	
Class A common stock	MNTS The Nasdaq Capital Market LLC		
Warrants	MNTSW	The Nasdaq Capital Market LLC	

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  $\boxtimes$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 2.02 Results of Operations and Financial Condition.

#### Item 7.01 Regulation FD Disclosure.

The following information is provided pursuant to Item 7.01 of Form 8-K, "Regulation FD Disclosure" and Item 2.02 of Form 8-K, "Results of Operations and Financial Condition."

On March 8, 2022, Momentus Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2021. In addition, the Company will be using a slide presentation during its earnings conference call. Copies of the press release and slide presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

This information and the information contained in Exhibits 99.1 and 99.2 are furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.

The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Exhibit Description
99.1	Press Release, dated March 8, 2022, issued by Momentus Inc.
99.2	Momentus Inc. Investor Presentation, dated March 8, 2022
104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: <u>/s/Jikun Kim</u> Name: Jikun Kim Title: Chief Financial Officer

Dated:

March 8, 2022



#### Momentus Inc. Announces Fourth Quarter and Full Year 2021 Financial Results

SAN JOSE, CA – March 8, 2021 – Momentus Inc. (NASDAQ: MNTS) ("Momentus" or the "Company"), a U.S. commercial space company that plans to offer transportation and other in-space infrastructure services, today announced its financial results for the fourth quarter ended December 31, 2021.

"We want to be a leading player in the emerging space transportation and infrastructure market," said Momentus Chief Executive John Rood. "We're focused on making this happen and are making meaningful progress. We've matured our technology through rigorous ground testing and assembly of Vigoride orbital transfer vehicles. We've signed Launch Services agreements with our strategic partner SpaceX for the inaugural launch of Vigoride and other missions in 2022 and 2023. And we've continued to develop our innovative Microwave Electrothermal Thruster using water as a propellant and are eager to demonstrate it in space."

#### Fourth Quarter 2021 Business Highlights:

- · Focused our efforts to bring our Vigoride orbital transfer vehicle to market.
- Completed assembly and initial system-level functional testing on the Vigoride-3 vehicle that we plan to fly on a demo mission later this year.
- Subsequent to the close of the quarter, we completed system-level thermal vacuum testing on Vigoride 3, which is late-stage environmental testing that simulates the environment in space.
- Completed Critical Design Review of our next-generation of Vigoride, called Block 2.2, to incorporate changes from the prior baseline. We now have three Block 2.2 vehicles in early stages of production.
- Signed a Launch Services Agreement that reserves two ports for Momentus on SpaceX's Transporter-5 mission, which is targeted for June of 2022. We plan to use one of these two ports for the inaugural mission of our Vigoride vehicle using Vigoride-3, which is designed to take our customers' satellites to custom orbits. Our launch plans remain subject to the receipt of licenses and other government approvals, and successful completion of our current efforts to get Vigoride and other space hardware ready for flight.
- We plan to use our second port on the Transporter-5 mission to aggregate ride-share demand from customers that do not require a custom orbit. We plan to use a deployer from a third party to place customer satellites in orbit.
- Subsequent to the close of the quarter, we signed Launch Services Agreements that reserve space for Vigoride on four follow-on SpaceX missions, including Transporter-6, which is targeted for October of 2022, Transporter-7, which is targeted for January of 2023, Transporter-8, which is targeted for April of 2023, and Transporter-9, which is targeted for October 2023.
- Established a Strategic Advisory Group comprised of five leaders and technology experts with world-class expertise and more than 150 years of combined experience in creating, implementing, and managing aerospace and technology businesses and programs for industry-leading companies and educational institutions.
- · Continued to make progress implementing our National Security Agreement, including meaningful progress upgrading and safeguarding our enterprise IT systems.

#### **Conference Call Information**

Momentus Inc. will host a conference call to discuss the results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) today. To access the conference call, parties should dial (844) 646-2696 and enter the conference ID number

9898339 (international participants should dial +1 (918) 922-6901). The live audio webcast along with supplemental information will be accessible on the Company's Investor Relations website at https://investors.momentus.space/events-and-presentations. A recording of the webcast will also be available following the conference call.

#### About Momentus Inc.

Momentus is a U.S. commercial space company that plans to offer in-space infrastructure services, including in-space transportation, hosted payloads and in-orbit services. Momentus believes it can make new ways of operating in space possible with its planned in-space transfer and service vehicles that will be powered by an innovative water plasma-based propulsion system that is under development. The Company anticipates flying its first Vigoride vehicle to Low Earth Orbit on a third-party launch provider as early as June 2022, subject to receipt of appropriate government licenses, approvals and availability of slots on its launch provider's manifest, for which there is no assurance such licenses, approvals and availability will be received, if at all.

#### Forward-Looking Statements

This press release contains certain statements which may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding Momentus or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. The words "may," "will," "anticipate," "believe," "expect," "continue," "could," "estimate," "future," "expect," "intends," "may," "might," "possible," "possible," "possible," "predict," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus' control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: the ability of the Company to obtain licenses and government approvals for its missions, which are essential to its operations; the ability of the Company to effectively market and sell satellite transport and in-orbit services; the ability of the Company to protect is intellectual property and trade secrets; the development of markets for satellite transport and in-orbit services; the ability of the Company to develop, test and validate its technology, including its water plasma propulsion technology; delays or impediments that the Company are fee in the development, manufacture and deployment of next generations sand business, including export control license requirements; the ability of attence or maintain a qualified workforce with the required security clearances and extensive and evolving government regulations that business, including export control license requirements; the ability of attence or product or raunch failures or delays that could lead customers to use competitors' services; investigations, claims, disputes, enforcement actions, litigation and/or other regulatory or legal proceedings; the effects of the COVID-19 pandemic on the Company business; the Company may be adversely affected by other economic, business, and/or competitive factors; and/or other risks and uncertainties included in the sectors' in the prospectus dated September 14, 2021 related to the Registration Statement on Form S-1 (No. 333-259281) filed by the Company or september 3, 2021, as such factors may be udated from time to time in our other filings with the Securities and Exchange Commission (the "SEC"), accessible on the SEC's website at www.sec.gov and t

#### MOMENTUS INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share data)

		nths Ended nber 31,	Year Decem	ended ber 31,
	2021	2020	2021	2020
Service revenue <sup>1</sup>	\$ —	\$ 365	\$ 330	\$ 365
Cost of revenue (decrease) <sup>2</sup>		368	(135)	368
Gross margin	_	(3)	465	(3)
Operating expenses:				
Research and development expenses	11,574	8,960	51,321	22,718
Selling, general and administrative expenses	13,103	4,467	48,905	11,945
Total operating expenses	24,677	13,427	100,226	34,663
Loss from operations	(24,677)	(13,430)	(99,761)	(34,666)
Other income (expense):				
Decrease (increase) in fair value of SAFE notes	_	(164,595)	209,291	(267,290)
Decrease (increase) in fair value of warrants	27,505	(1,860)	37,330	(3,177)
Realized loss on disposal of asset	(17)	(482)	(17)	(482)
Interest income		_	2	7
Interest expense	(5,544)	(324)	(14,229)	(470)
SEC settlement	_	_	(7,000)	_
Other income (expense) <sup>3</sup>	5	(7)	(4,960)	(949)
Total other income (expense)	21,948	(167,268)	220,417	(272,360)
Income (loss) before income taxes	(2,728)	(180,698)	120,656	(307,026)
Income tax provision	1	_	2	1
Net income ( loss)	\$ (2,729)	\$ (180,698)	\$ 120,654	\$ (307,027)
Net income ( loss) per share, basic	\$ (0.05)	\$ (2.88)	\$ 1.85	\$ (4.90)
Net income (loss) per share, fully diluted	\$ (0.05)			
Weighted average shares outstanding, basic	60,589,566	62,722,340	65,177,873	62,643,121
Weighted average shares outstanding, fully diluted	60,589,566	62,722,340	70,918,777	62,643,121

1 - Revenue recognized related to cancellations of customer contracts, resulting in the forfeiture of customer deposits

2 - The reduction of cost of revenue represents the reversal of a contingency recorded during the prior year for loss contracts related to free slots on future missions. During the prior three months ended September 30, 2021, the Company signed amendments or terminations with those customers such that the services will no longer be free of charge. The reversed contingency was offset by costs incurred related to one of the cancelled contracts.

3 - Other expenses during the twelve months ended December 31, 2021 were due to the transaction costs allocated to the liability-classified warrant assumed in connection with the Business Combination. Other expense in the twelve months ended December 31, 2020 was due to banking fees related to SAFE financing raised during the period.

# MOMENTUS INC. CONSOLIDATED BALANCE SHEETS (in thousands)

(in thousands)		
	December 31, 2021	December 31, 2020
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 160,036	\$ 23,005
Restricted cash, current	197	100
Prepaids and other current assets	9,431	4,508
Total current assets	169,664	27,613
Property, machinery and equipment, net	4,829	2,321
Intangible assets, net	349	305
Operating right-of-use asset	7,604	316
Deferred offering costs	_	2,610
Restricted cash, non-current	314	415
Other non-current assets	3,065	2,740
Total assets	\$ 185,825	\$ 36,320
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)		
Accounts payable	1,911	1,863
Accued expenses	9,785	3,064
Loan payable, current	20,907	
Contract liabilities, current		1,914
Operating lease liability, current	1,189	254
Other current liabilities	5,075	220
Total current liabilities	38,867	7,314
Contract liabilities, non-current	1,554	711
Warrant liability	5,749	3,206
SAFE notes		314,440
Operating lease liability, non-current	7,284	72
Other non-current liabilities	483	49
Total non-current liabilities	15,070	318,478
Total liabilities	53,937	325,792
Shareholders' equity (deficit):		
Common stock, \$0.00001 par value; 250,000,000 shares authorized and 81,211,781 issued and outstanding as of December 31, 2021; 142,804,498 shares authorized and 62,510,690 issued and outstanding as of December 31, 2020	1	1
Additional paid-in capital	340,570	39,866
Accumulated deficit	(208,683)	(329,338)
Total shareholders' deficit	131,888	(289,472)
Total Liabilities and Shareholders' Deficit	\$ 185,825	\$ 36,320

Total shareholders' deficit	
Total Liabilities and Shareholders' Deficit	\$

# MOMENTUS INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

(in thousands)				
	Year end 2021	Year ended December 31, 2021 2020		
Cash flows from operating activities:			2020	
Net income (loss)	\$ 120,6	54 \$	(307,027)	
Adjustments to reconcile net income (loss) to net cash used in operating activities:				
Depreciation and amortization	1,0	92	590	
Amortization of debt discount and issuance costs	11,7	29	116	
Increase in fair value of warrants	(37,3	30)	3,177	
Increase in fair value of SAFE notes	(209,2)	91)	267,290	
Impairment of prepaid launch costs	9,4	50	1,500	
Loss on disposal of fixed and intangible assets		17	482	
Stock-based compensation expense	18,4	52	2,771	
Changes in operating assets and liabilities:				
Prepaids and other current assets	(14,3)	73)	(3,616)	
Other non-current assets	(3)	25)	(760)	
Accounts payable	1,5	62	(997)	
Accrued expenses	7,0	42	1,813	
Other current liabilities	4,8	10	211	
Contract liabilities	(1,0	71)	1,916	
Lease liabilities and right-of-use assets	8	59	_	
Other non-current liabilities		11	—	
Net cash used in operating activities	(86,7	12)	(32,534)	
Cash flows from investing activities:				
Purchase of property, machinery and equipment	(2,9	72)	(1,502)	
Purchases of intangible assets	(1	18)	(99)	
Net cash used in investing activities	(3,0)	<del>)</del> 0)	(1,601)	
Cash flows from financing activities:				
Proceeds from issuance of SAFE notes	30,8		44,650	
Proceeds from issuance of loan payable	25,0		2,458	
Proceeds from exercise of stock options		36	91	
Payment for repurchase of Section 16 Officer common shares for tax coverage exchange	(1)			
Payment of notes payable	(1,5)		(2,507)	
Payment of debt issuance costs		44)	(37)	
Payment of warrant issuance costs		31)	(1)	
Payment for repurchase of common shares	(40,0		_	
Proceeds from issuance of common shares in PIPE	110,0		-	
Payments of issuances costs related to PIPE	(4,4		—	
Proceeds from issuance of common stock upon Business Combination	128,1		-	
Payments for issuance costs related to Business Combination	(21,2)		—	
Net cash provided by financing activities	226,8	29	44,654	
Increase in cash and cash equivalents	137,0		10,519	
Cash and cash equivalents, beginning of period	23,5		13,002	
Cash and cash equivalents, end of period	\$ 160,5	47 \$	23,520	
Supplemental disclosure of non-cash investing and financing activities				
Issuance of common stock related to conversion of SAFE notes	\$ 136.0	01 \$	_	
Issuance of common stock related to conversion of SATE notes		99 \$	_	
Reclassification of deferred offering costs		10 \$		
Deferred offering costs in accounts payable and accrued expenses at period end		10 \$ 	506	
Assumption of merger warrants liability		\$ 25 \$	506	
	\$ 31,2		_	
Operating lease right-of-use assets in exchange for lease obligations	6,5	)1	_	
Supplemental disclosure of cash flow information				
Cash paid for income taxes	S	1 \$	1	
Cash paid for interest	*	00 \$	353	
The second se	φ 2,5	··· -	555	

#### Reclassifications

Certain reclassifications have been made to the prior year's financial statements to conform to the current year's presentation. None of the reclassifications have changed the total assets, liabilities, shareholders' deficit, income, expenses or net losses previously reported.

#### Use of Non-GAAP Financial Measures (unaudited)

This press release references certain non-GAAP financial measures, including adjusted EBITDA, non-GAAP selling, general, and administrative expense and non-GAAP research and development expense. The Company defines adjusted EBITDA as earnings before interest expense, taxes, depreciation and amoritation, stock-based compensation, and certain other items the Company believes are not indicative of its core operating performance. The Company defines non-GAAP selling, general, and administrative expenses and research and development expenses as those respective GAAP amounts, excluding stock-based compensation and non-recurring items not indicative of core operating performance. None of these non-GAAP financial measures is a substitute for or superior to measures of financial performance prepared in accordance with generally accepted accounting principles in the United States (GAAP) and should not be considered as an alternative to any other performance measures derived in accordance with GAAP.

The Company believes that presenting these non-GAAP financial measures provides useful supplemental information to investors about the Company that is helpful in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational-decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.

#### Full year adjusted EBITDA

A reconciliation of adjusted EBITDA to net loss for the years ended December 31, 2021, and December 31, 2020 is set forth below:

	Year E	Year Ended December 31		
	2021	2021		
Net Income (Loss)	\$ 120,	54 \$	(307,027)	
Income tax expense		2	1	
Interest income		(2)	(7)	
Interest expense	14,	229	470	
Depreciation & amortization	1,	)92	590	
EBITDA	135,	975	(305,974)	
(Decrease) increase in fair value of SAFE notes	(209,	.91)	267,290	
(Decrease) increase in fair value of warrants	(37,	30)	3,177	
Realized loss on disposal of assets		17	482	
SEC settlement	7,	000	_	
Transaction costs allocated to warrant liability	4,	780	_	
Investment banking fees related to SAFE financing		175	1,005	
Prepaid launch deposit impairment	9,	450	1,500	
SEC and CFIUS legal expenses	10,	)38	_	
Reduction in SEC and CFIUS legal expenses due to fee dispute resolution	(2,	51)	—	
Class action litigation legal expenses		352	_	
SEC compliance costs	1,	)73	_	
NSA compliance costs	1,	335	_	
Severance and other related expenses		136	268	
Stock-based compensation	18,	152	2,771	
Adjusted EBITDA	\$ (59,	\$ (88	(29,482)	

A reconciliation of selling, general, and administrative expenses to non-GAAP selling, general, and administrative expenses for the years ended December 31, 2021 and December 31, 2020, is set forth below:

	Year Ended Decen	nber 31
(in thousands)	 2021	2020
Selling, general, and administrative expenses	\$ 48,905 \$	11,945
Stock-based compensation	16,110	2,584
SEC and CFIUS legal expenses	10,038	_
Reduction in SEC and CFIUS legal expenses due to fee dispute resolution	(2,551)	_
Class action litigation legal expenses	852	_
SEC compliance costs	1,073	_
NSA compliance costs	1,835	_
Severance and other related expenses	63	110
Non-GAAP selling, general, administration expenses	\$ 21,483 \$	9,251

A reconciliation of research and development expenses to non-GAAP research and development expenses for the years ended December 31, 2021, and December 31, 2020, is set forth below:

	Year Ended December 31		
(in thousands)		2021	2020
Research and development expenses	\$	51,321	\$ 22,718
Prepaid launch deposit impairment		9,450	1,500
Stock-based compensation		2,341	188
Severance and other related expenses		74	158
Non-GAAP Research and development expenses	\$	39,456	\$ 20,873

#### Quarterly adjusted EBITDA

A reconciliation of adjusted EBITDA to net loss for the three months ended December 31, 2021, December 31, 2020, and September 30, 2021, is set forth below:

	Three Months Ended			
(in thousands)		December 31, 2021	December 31, 2020	September 30, 2021
Net Income (Loss)	\$	(2,729)	\$ (180,698)	\$ (5,614)
Income tax expense		1	_	_
Interest income		_	—	—
Interest expense		5,544	324	4,328
Depreciation & amortization		324	171	320
EBITDA		3,140	(180,202)	(966)
(Decrease) increase in fair value of SAFE notes		_	164,595	(26,924)
(Decrease) increase in fair value of warrants		(27,505)	1,860	2,712
Realized loss on disposal of assets		17	482	—
Transaction costs allocated to warrant liability		_	_	4,780
Prepaid launch deposit impairment		_	1,500	—
SEC and CFIUS legal expenses		464	_	2,188
Reduction in SEC and CFIUS legal expenses due to fee dispute resolution		(2,551)	—	—
Class action litigation legal expenses		797	_	54
SEC compliance costs		1,073	—	—
NSA compliance costs		905	_	882
Severance and other related expenses <sup>1</sup>		(13)	110	(7)
Stock-based compensation		7,265	1,129	3,075
Adjusted EBITDA	\$	(16,407)	\$ (10,527)	\$ (14,207)

1 - Loss contingencies for certain severance agreements were reversed when the Company determined they would not be signed and paid

A reconciliation of selling, general, and administrative expenses to non-GAAP selling, general, and administrative expenses for the three months ended December 31, 2021, December 31, 2020, and September 30, 2021, is set forth below:

	Three Months Ended		
(in thousands)	December 31, 2021	December 31, 2020	September 30, 2021
Selling, general, and administrative expenses \$	13,103	\$ 4,467	\$ 12,057
Stock-based compensation	5,109	1,050	3,023
SEC and CFIUS legal expenses	464	—	2,188
Reduction in SEC and CFIUS legal expenses due to fee dispute resolution	(2,551)	_	_
Class action litigation legal expenses	797	—	54
SEC compliance costs	1,073	_	_
NSA compliance costs	905	—	882
Severance and other related expenses <sup>1</sup>	(13)	110	_
Non-GAAP selling, general, administration expenses	7,318	\$ 3,306	\$ 5,910

1 - Loss contingencies for certain severance agreements were reversed when the Company determined they would not be signed and paid

A reconciliation of research and development expenses to non-GAAP research and development expenses for the three months ended December 31, 2021, December 31, 2020, and September 30, 2021, is set forth below:

		Three Months Ended	
(in thousands)	December 31, 2021	December 31, 2020	September 30, 2021
Research and development expenses	\$ 11,574	\$ 8,960	\$ 9,047
Prepaid launch deposit impairment	_	1,500	—
Stock-based compensation	2,156	78	52
Severance and other related expenses <sup>1</sup>	—	_	(7)
Non-GAAP Research and development expenses	\$ 9,418	\$ 7,382	\$ 9,002

1 - Loss contingencies for certain severance agreements were reversed when the Company determined they would not be signed and paid

#### For media inquiries:

press@momentus.space

#### For investor relations inquiries:

investors@momentus.space



#### Disclaimer and Cautionary Note Regarding Forward-Looking Statements

The presentation contains owners which constants "forward-locking statements which the meaning of Section 274 of the Socurities Act of 1923 and Section 215 of the Exchange Act of 1934. Forward-locking statements include, but are not interference on an another the section 215 of the Exchange Act of 1934. Forward-locking statements include, but are not interference on an another the section 215 of the Section 2

The technology underlying our anticipated service offerings is still in the process of being developed, and has not been fully tested or validated in space. Our ability to execute on our business plan is dependent on the successful development and commendization of our technologies. Development of space technologies is a determedy complex, time community, and expensive, and there can be no assumed that our predicted theoretical and goound-based results will translate into operational procession. Development of space technologies is a determedy complex, time community, and expensive, and there can be no assumed that our predicted theoretical and goound-based results will translate into operational procession. Development of space technologies is a determedy complex, time and procession and goound-based results will accepted to come and accessful complex time and procession and accessful complex time and procession. Development and accessful complex time and procession and accessful complex time and procession and goound-based results will be accessible on the space and development and accessful complex time and procession and goound-based results will be accessful complex time and procession and goound-based results will be accessful complex time and processful complex time and procession and development and accessful complex time and procession and development and accessful complex time and procession accessible on a development accessible on the space accessible on a development accessible on the space accessible on the space accessible on the space accessible on a development accessible on the space accessibl

Use of Non-GAAP Francial Measures
This presention references contain non-GAAP financial measures, including adjusted EBITDA, non-GAAP selling, general, and administrative asponse and non-GAAP research and development speense. Momentus defines adjusted EBITDA as
administrative expenses and research and development expenses and non-GAAP instance. Momentus administrative asponses and non-GAAP research and development expenses. Including adjusted EBITDA as
administrative expenses and research and development expenses as those negocities of AAP annotative, social data administrative expenses and non-GAAP instance. Momentus administrative expenses and non-GAAP instance. Momentus administrative expenses and research and development expenses as those negocities of AAP annotative expenses. The second containes of the general performance properties in the second contained as administrative expenses. The binde Data of the contexperse administrative expenses and research and development expenses. The second containes of the general performance properties in the binde Data of the contexperse administrative expenses. The contexperse administrative expenses and research and development expenses and research and development expenses and research and development expenses. The second containes of the contexperse administrative expenses and research and development expenses. These non-GAAP intervalses are non-GAAP intervalses and non-GAAP intervalses are non-GAAP intervalses. The contexperse administrative expenses are non-GAAP intervalses. The contexperse administrative expenses are non-GAAP intervalses are non-GAAP intervalses. The contexperse administrative expenses are non-GAAP intervalses. The contexp

Interactions wereted in Eccentration term GAMP financial measures provides useful supplemental information to investors about Momentus that is helpful in understanding and evaluating its operating results, enhancing the overall understanding of the part of the provide transport of the provide tr

Copyright 2022. Momentus Inc. Not Export Controlled. Any use, reproduction, or distribution without the express consent of Momentus is strictly prohibited.

### **Recent Progress**

- Continued work to bring Vigoride orbital transfer vehicle to market.
- Completed assembly and initial system-level functional testing of Vigoride 3.
- Subsequent to quarter end, we completed system-level thermal vacuum testing of Vigoride 3.
- Continue to believe that Vigoride 3 is on a path to complete ground tests in time for inaugural launch.
- Signed Launch Services Agreements (LSAs) for two ports on SpaceX Transporter-5 mission, targeted for June 2022.
- Subsequent to quarter end, we signed LSAs for four additional SpaceX missions including:

   Transporter-6, targeted for October 2022 \*
   Transporter-8, targeted for April 2023 \*
   Transporter-9, targeted for October 2023 \*
- Established Strategic Advisory Group comprised of five leaders and technology experts to advise company leadership on
  programmatic, technical, and operational matters.
- Subsequent to quarter end, welcomed Jason Garkey as new Security Officer, reporting to Security Director Vic Mercado.
- Made good progress implementing compliance tasks required under NSA including majority of IT modernization plan.
- Copyrget 2022. Momenta is:: Not Export Controlled. May use, reproduction, or distribution without the segress consult of Momenta is strictly prohebited.

# Execution Toward Strategy

Element of Strategy	Recent progress point(s)
Bring Vigoride to market soon and with required features and reliability.	<ul> <li>Launch Services Agreement (LSA) with SpaceX for inaugural mission as early as June '22.*</li> <li>Signed LSAs for additional SpaceX ports in Oct '22, Jan '23, Apr '23, and Oct '23.*</li> <li>Completed Critical Design Review on next generation (Block 2.2) Vigoride design.</li> </ul>
Make Vigoride reusable and expand its capabilities beyond hub-and-spoke transportation mission.	<ul> <li>Plan to carry at least one Hosted Payload in 2022.</li> <li>Working to develop requisite technologies for reusability and satellite-to-satellite services such as in-orbit maintenance, refueling and de-orbiting.</li> </ul>
Broaden service offering into adjacent markets.	<ul> <li>Using one of two June ports to launch a third-party product designed to deploy customer satellites directly from the launch vehicle (no orbital transfer vehicle).</li> <li>Meets needs of customers who don't require a precise orbit more economically than woul be possible with a more capable, but also more expensive, Vigoride vehicle.</li> </ul>
Continuous innovation.	<ul> <li>Continuing work to develop robotic arm, sensor packages, fluid transfer system, propulsion and power systems and other novel technologies.</li> <li>Applicable to Vigoride block upgrades or larger future vehicles.</li> </ul>
Attract, develop, and retain a highly- skilled and motivated workforce.	<ul> <li>Hired new Security Officer who is already making a big difference on NSA implementation.</li> <li>Continued building out our engineering staff and restructuring our organizational design.</li> <li>Made new resources available to engineers including new Strategic Advisory Group.</li> </ul>
Copyright 2022. Momentus Inc. Not Esport Controlled. Any uses ra distribution without the express consent of Momentus is strictly pro-	• Our launch plans remain subject to the receipt of licenses and other government approvals, and

#### **Execution Plan** Vigoride 2 Vigoride 1 Vigoride 3 Vigoride 5 \*\* NI Vigoride schedule (as of March 8, 2022) System Build & Verification Phase Unit Qual Sys PreEnv TVAC Vibe Env Cust. Int. LV Int. Design Phase CODR PDR CDR Launch Vigoride 1 Vigoride 2 Vigoride 3 Vigoride 5 In Process These photos are Not Export Controlled and contain no Protected Technical Information. Copyright 2022. Momentus Inc. Not Export Controlled. Any use, reproduction, or distribution without the express consent of Momentus is strictly prohibited.

### Fourth Quarter Financial Highlights

- \$67 million in backlog (potential revenue), as of January 31, 2022. \*
- Non-restricted cash and cash equivalents of approximately \$160 million as of December 31, 2021.
- Gross debt of approximately \$25M, consisting of a term loan that we will begin to repay in March.
- Revenue recognition will begin when we start flying customers to space.
- Q4 loss from operations at approximately \$24.7 million.
- Q4 Adjusted EBITDA was negative \$16.4 million.
- Adjusted EBITDA excludes stock-based compensation expense, certain legal matters, and net markto-market gains and losses on warrant liabilities, and other adjusting items.
- Refer to the Appendix of this presentation for reconciliation with equivalent GAAP quantities.

\* Backgo contains firm orders as well as options, which allow customers to opt-in to launches on shorter notice without requiring a separate agreement. The breadth of these signed contracts spans across 24 companies in 15 countries. In general, our customers have the right to cancel their contracts with the understanding that they will forgo their deposits. If a customer cancels a contract before it is required to pay non-refundable deposits, we may not needve revenue from these orders, except for an initial deposit which is paid at the time the contract is signed.


Copyright 2022, Momentus Inc. Not Export Controlled. Any use, reproduction, or distribution without the express consent of Momentus is strictly prohibited.





### Income Statement

	Three Mont	ns Ended Dec	ember 31,	Year er	nded Decemb	er 31,	
	12/31	2021	12/31/2020	1	2/31/2021		12/31/2020
Service revenue	\$	- \$	365	\$	330	\$	365
Cost of revenue (decrease)		-	368	1.1.1	(135)		368
Gross margin			(3)		465		(3
Operating expenses:							
Research and development expenses	1	1,574	8,960		51,321		22,718
Selling, general and administrative expenses	1	8,103	4,467		48,905		11,945
Total operating expenses	2	1,677	13,427		100,226		34,663
Loss from operations	(2	1,677)	(13,430)		(99,761)	_	(34,666
Other income (expense):							
Decrease (increase) in fair value of SAFE notes			(164,595)		209,291		(267,290
Decrease (increase) in fair value of warrants	2	7,505	(1,860)		37,330		(3,177
Realized loss on disposal of asset		(17)	(482)		(17)		(482
Interest income		0	0		2		7
Interest expense	(	5,544)	(324)		(14,229)		(470
SEC settlement					(7,000)		
Other income (expense) 3		5	(7)	1.0	(4,960)		(949
Total other income (expense)	2	1,948	(167,268)		220,417		(272,360
income (loss) before income taxes	(	2,728)	(180,698)	1000	120,656	-	(307,026
Income tax provision		1	-		2		1
Net income ( loss)	\$ (	2,729) \$	(180,698)	\$	120,654	\$	(307,027
Net income ( loss) per share, basic	\$	(0.05) \$	(2.88)	\$	1.85	\$	(4.90
Net income ( loss) per share, fully diluted	\$	(0.05) \$	(2.88)	\$	1.70	\$	(4.90
Weighted average shares outstanding, basic	60,58	,566	62,722,340		55,177,873		62,643,121
Weighted average shares outstanding, fully diluted	60,58	,566	62,722,340		70,918,777		62,643,121



## **Cash Flow Statement**

Supplemental disclosure of non-cash investing and financing activities Fair value of common tock issued upon conversion of SAF non-text 136,001 Fair value of common tock issued upon conversion of Vart networks 6,099 Reclassification of diverse of text	12/31/202
Proceeds from resurve of losa payable         25.000           Proceeds from resurve of losa payable         25.000           Payment of respurchase of section 16 Officer common shares for tax coverage         (15.1)           Payment of respurchase of section 16 Officer common shares for tax coverage         (15.1)           Payment of other submarks of section 16 Officer common shares for tax coverage         (15.0)           Payment of lowarized common shares         (11.1)           Payment of lowarized common shares         (11.000)           Payment of lowarized common shares         (12.0)           Payment of lowarized common shares         (22.6.29)           Cask cosh equivalents and restricted cash         (127.02)           Cask, cash equivalents and restricted cash. beginning of period         (23.50)           Cash, cash equivalents and restricted cash. beginning of period         (35.00)           Sari value of common stock sized upon conversion of SAF Incole.         (21.0)           Sari value of common stock sized upon conversion of sari values         6.999           Residuaritation target conversion of sari restricted cash. Payment of user cash conversion of sari rations         (21.2)           Sari value of common stock sized upon conversion of sari rations         (3.2)         (3.2)           Cash, cash equivalents and restricted cash. Paymentof sari ratio sari value of common stock sized upon conversion of	
Processiti nom exercise of stacks option         386           Payment for regurs/use of stacks in 50 officer common shares for tax coveragi         (151)           Payment of rotes payable         (150)           Payment of rotes payable         (150)           Payment of ordes payable         (150)           Payment of suance costs - shares         (161)           Payments of suance costs related to NPE         (1500)           Payments of suance costs related to NPE         (1500)           Cat, cash equivalents and restricted cash         (226,23)           Increase in cash, cash equivalents and restricted cash         (216,25)           Supplemental disclosure of non-scale shares         (150,00)           Fair value of common stock issued upon conversion of SATE cash (150,00)         (151,00)           Fair value of common stock issued upon conversion of sATE cash (150,00)         (151,00)           Fair value of common stock issued upon conversion of sATE cash (150,00)         (151,00)           Fair value of common stock issued upon conversion of sATE cash (150,00)         (151,00)           Fair value of common stock issued upon conversion of sATE cash (150,00)         (151,00)	44,6
Payment of responsibles of Section 8.0 Officer common shares for tax coveragi         (13)           Payment of obelt issuance costs         (144)           Payment of obelt issuance costs         (144)           Payment of obelt issuance costs         (11)           Payment of obelt issuance costs         (11)           Payment of responsibles of common shares         (11)           Payment of responsibles of common shares         (11)           Payment of summa costs related to IPIF.         (11)           Payments for summa costs related to IPIF.         (12)           Payments for summa costs related to IPIF.         (12)           Payments for summa costs related to IPIF.         (12)           Text cash provided by financing activities         (12)           Cash, cash equivalents and restricted cash.         (12)           Cash, cash equivalents and restricted cash. Beginning of period         (13)           Cash, cash equivalents and restricted cash. Beginning of period         (13)           Fair value of common tock issued upon conversion of Variants         6,999           Reclassification of differed of bering costs in accounts of Variants         6,999           Defermed offering costs in accounts payable and accued septenses at period         -           Operating lease right of-use assets in texchareg for lease obligations         3,212     <	2,4
Payment of notes payable         11,500           Payment of notes payable         10,401           Payment of variant issuance costs         10,101           Payment of variant issuance costs         10,100           Proceeds from issuance of common shares         40,000           Proceeds from issuance of common shares in PPE         110,000           Payment of regularized costs related to Ruiness Combination         12,2523           Increase in cash, cash equivalents and restricted cash         17,007           Cash, cash equivalents and restricted cash beginning of period         23,5300         5           Cash, cash equivalents and restricted cash more from domarcing activities         166,001         5           Payment of forescash investing and francing, activities         2,580         5           Payment of forescash investing and francing, activities         2,580         5           Payment activities of investing and marcing activities         3,580         5         5           Payment activities of investing and marcing activities         2,580         5         5         5           Deferred differing costs in Accord appress at period end         3,1225         5         5         5         5         5         5         5         5         5         5         5         5         5	1
Payment of obeli issuance costs         (144)           Payment of ovarrants issuance costs         (11)           Payment of respurchase of common shares         (40,00)           Payment of respurchase of common shares         (40,00)           Payment of respurchase of common shares         PPC           Payment of respurchase of common shares         (44,16)           Payments of respurchase of common shares         (21,25)           Wet cash provided by financing activities         (22,52,7)           Cash, cash equivalents and restricted cash. begioning of period         23,250           Cash, cash equivalents and restricted cash. begioning of period         51,60,47           Sary bane common stock issue dup conversion of SAR tracks         6,999           Residualitation of defined coftering costs in Acto Save dup conversion of SAR tracks         6,999           Defined of define costs in Acto Save dup conversion of SAR tracks         6,591           Operating lease right of-use assets in excharge for lease obligations         3,501           Supplementation define costs in account save dup conversion of SAR tracks         6,501           Cash ach equivalents and restricted cash period end         -           Cash ach equivalent of-use assets in excharge for lease obligations         8,501           Supplementation define costs         2,501           Cash ach eq	
Payment of variant issuance costs         (31)           Payment for yearchies of common shares in PPE         110,000           Proceeds from issuance of common shares in PPE         110,000           Payment for issuance costs related to INUERS Combination         (21,255)           Lives can provided by Imanding activities         26,852           Increase in cash, cash equivalents and restricted cash         137,007           Cash, cash equivalents and restricted cash         13,000           Jack, cash equivalents and restricted cash         13,000           Cash, cash equivalents and restricted cash         13,000           For value of common stock issed uptor conversion of SAF runk         136,000           Pair value of common stock issed uptor conversion of SAF runk         6,990           Pair value of common starces in a provide and scrude appress at period error         2,100           Deferred differing costs in locations payable at period runk         1,225           Operating lease right of-sure assets in exchange for lease obligations         8,501           Supplemental disclosure of con-locations tomestom         8,501           Supplemental disclosure of con-locations tomestom         8,501           Supplemental disclosure of con-locations tomestom         8,501           Supplemental disclosure of con-locations tomestom solid for runkeer star runkeer star runkeer star runkeer starest	(2,5
Payment for regarchase of common shares         (40,000)           Payments of susance of common shares INPIC         (10,000)           Payments of susance costs related to INPIC         (4,416)           Payments of susance costs related to Ruless Combination         (22,587)           Vet cash provided by financing activities         (23,537)           Cash, cash equivalents and restricted cash         (23,537)           Fair value of common tack issuid upon conversion of SAF (conversion of SAF (conver	(
Proceeds from issuance of common shares in PPE         110.000           Payments of issuance costs related to PBF         (4,46)           Payments for issuance costs related to Isuines Combination         (21,285)           Lite cash povided by Imanding activities         226,829           Increase in cash, cash equivalents and restricted cash         137,027           Cash, cash equivalents and restricted cash beginning of period         3106,001           Stark, cash equivalents and restricted cash more resting of period         3106,001           Fair value of common took issued upon conversion of S4 finities         6,999           Fair value of common stock issued upon conversion of S4 more period         12,225           Operand differing costs in lacross repative and encroad equiperses a tend of error         12,225           Operanding leave right of use assets in exchange for lease obligations         8,501           Supplemental disclosure of can how information         2,125           Operanding leave right of use assets in exchange for lease obligations         8,501           Supplemental disclosure of can how information         8,501	
Payments of issuance costs related to INPE         (4.416)           Payments for issuance costs related to INNEss Combination         (22.852)           Net cash provided by financing activities         226.832           Cash, cash qualvalents and restricted cash         117.027           Cash, cash qualvalents and restricted cash         236.832           Frair Value of commons for SATE Crists         155.001           Fair value of common tock issuid upon conversion of SATE Crists         6.999           Reclassification of derend of Engr costs to APIC	
Payments for issuance costs related to Bulaness Combination         [21,285)           Viet cash provided by financing activities         226,829           Direnses in cash, cash equivalents and restricted cash         137,027           Cash, cash equivalents and restricted cash beginning of period         23,530           Cash, cash equivalents and restricted cash beginning of period         23,500           Cash, cash equivalents and restricted cash investing and financing activities         156,001           Fair value of common tock issued upon conversion of 347 incost         56,001           Fair value of common stock issued upon conversion of 347 incost         5,001           Fair value of common stock issued upon conversion of 347 incost         6,999           Residuaritation of differing costs in bison payble at period effect         1           Deferred differing costs in bison payble at period rest         1           Tar value of averances combination         3,1225           Operating lease right of-use assets in exchange for lease obligations         8,501           supplemental disclosure of cash flow information         24,225	
Viet cab provided by financing activities         225.823           Increase in cab, cab equivalents and restricted cash         137.027           Cab, cab equivalents and restricted cash beginning of period         32.500           Cab, cab equivalents and restricted cash, end of period         5.100.547.000           Fair vabe of commony of non-cash investing and financing activities         6.999           Reclassification of deferred offering costs to APIC         2.5100           Deferred offering costs in Accounts perpensis at period er         -           Deferred offering costs in Accounts payable at period er         -           Deferred offering costs in exchange profess combination         31.225           Operanting lesser right-of-use assets in exchange for lesse obligations         8.501           supplemental discourse of table for how information         2.125	
Increase in cash, cash equivalents and restricted cash IT27.027 Cash, cash equivalents and restricted cash beginning of period IT23.230 Cash, cash equivalents and restricted cash models and of period IT23.230 Supplemental disclosure of non-cash investing and financing activities Fair value of common tack issued upon conversion of VAR increase Fair value of common tack issued upon conversion of VAR increase Fair value of common stock issued upon conversion of VAR increase Fair value of common stock issued upon conversion of VAR increase Educationation of defined offering costs in accounts payvable and account expenses at period er Fair value of common stock insue upon conversion of VAR increase Fair value of variants assumed upon functions Common table in the cash in exchange for lease obligations Supplemental disclosure of cash flow information Cash paird of increases 1	
Cash, cash equivalents and restricted cash, beginning of period         23,200           Cash, cash equivalents and restricted cash, end of period         5,100,470         5           Stray band reamments and restricted cash, beginning of period         5,100,470         5           Stray band reamments and restricted cash, beginning of period         5,100,470         5           Fair value of common tock issued upon conversion of SAF renorms         6,099         6           Reclassification of defined of being costs to APC         -         0           Defined of offering costs in accounts up value and accrued septents at period         -         -           Operating lease right of-use assets in exchange for lease obligations         8,501         -           Supplemental disclosure of cash flow information         2,225         -         -           Cash paid for income taxes         1         -         -         -	44,6
Cash, cash equivalents and restricted cash, beginning of period         23,200           Cash, cash equivalents and restricted cash, end of period         5,100,470         5           Stray band reamments and restricted cash, beginning of period         5,100,470         5           Stray band reamments and restricted cash, beginning of period         5,100,470         5           Fair value of common tock issued upon conversion of SAF renorms         6,099         6           Reclassification of defined of being costs to APC         -         0           Defined of offering costs in accounts up value and accrued septents at period         -         -           Operating lease right of-use assets in exchange for lease obligations         8,501         -           Supplemental disclosure of cash flow information         2,225         -         -           Cash paid for income taxes         1         -         -         -	
Cash, cash equivalents and restricted cash, end of period         5         6         5         6	10.5
Supplemental disclosure of non-cash investing and financing activities Fair value of common tack issued upon conversion of SAF non-text 136,001 Fair value of common tack issued upon conversion of Vart networks 16,099 Reclassification of diverse of text of tex	13.0
Fair value of common stock issud upon conversion of SAFL notes     136.001       Fair value of common tock usiou upon conversion of variants     6.999       Reclassification of deferred offering costs to APIC     2.500       Deferred offering costs in Accurso approach and accurde approach     -       Deferred offering costs in Accurso approach     3.125       Operanding lease right of-ure assets in exchange for lease obligations     8.501       Supplemental disclosure of cash flow information     1       Coth paid for increase tasys with a start of the start	\$ 23.519.
Fair value of common stock issud upon conversion of SAFL notes     136.001       Fair value of common tock usiou upon conversion of variants     6.999       Reclassification of deferred offering costs to APIC     2.500       Deferred offering costs in Accurso approach and accurde approach     -       Deferred offering costs in Accurso approach     3.125       Operanding lease right of-ure assets in exchange for lease obligations     8.501       Supplemental disclosure of cash flow information     1       Coth paid for increase tasys with a start of the start	
Fair value of Common stock issued upon conversion of warrants     6,999       Reclassification of diverse of being costs to APIC     2,010       Deferred offering costs in accounts payable and accrued segmens at period     -       Deferred offering costs in losins payable and accrued segmens at period     -       Fair value of warrants assumed upon Bulness Combination     31,225       Operating lases regin of our saves in exclusing for fasts ablightons     8,501       Supplemental disclosure of cash flow information     2,125	
Reclassification of deferred offering costs to APIC         2,500           Deferred offering costs in accursts payled and accured expenses at period err         -           Deferred offering costs in loss no paylele at period error         3,225           Operanding less registrations         3,225           Operanding less registrations         8,501           supplemental disclosure of cash flow information         2,250           Cash paid for increase tasks         1	
Deferred offering costs in accounts symphile and accrued expenses at period er Deferred offering costs in loans payable at period end flar value of warrants summed upon Buliness Combination 31,225 Operating leave right-of-use assets in exchange for lease obligations 8,501 Supplemental disclosure of cash flow information Cash paid for increases 1	
Deferred offering costs in losin synable at period end	5
Fair value of warrants assumed upon Business Combination 31.225 Operating lease right-of-us a sets in exchange for lease obligations 8,501 Supplemental disclosure of cash flow information Cash pial for income taxes 1	
Operating lease right-of-use assets in exchange for lease obligations 8,501 Supplemental disclosure of cash flow information Cash paid for income taxes 1	
Cash paid for income taxes 1	
Cash paid for interest 2,500	3
Cash paid for intere	ne taxes 1

### GAAP to Non-GAAP Reconciliation – Adj. EBITDA

Quarterly adjusted EBITDA A reconciliation of adjusted EBITDA to net loss for the three months ended December 31, 2021, December 31, 2020, and September 30, 2021, is set forth below:

	Three Months Ended						
(in thousands)	December 31, 2021		December 31, 2020		September 30, 2021		
Net Income (Loss)	\$	(2,729)	\$	(180,698)	\$	(5,614)	
Income tax expense		1		-		-	
Interest income		-		-		-	
Interest expense		5,544		324		4,328	
Depreciation & amortization		324		171		320	
EBITDA		3,140		(180,202)		(966)	
(Decrease) increase in fair value of SAFE notes		-		164,595		(26,924)	
(Decrease) increase in fair value of warrants		(27,505)		1,860		2,712	
Realized loss on disposal of assets		17		482		_	
Transaction costs allocated to warrant liability		-		-		4,780	
Prepaid launch deposit impairment				1,500		_	
SEC and CFIUS legal expenses		464		_		2,188	
Reduction in SEC and CFIUS legal expenses due to fee dispute		(2,551)		_			
Class action litigation legal expenses		797		-		54	
SEC compliance costs		1,073		-		-	
NSA compliance costs		905		-		882	
Severance and other related expenses1		(13)		110		(7	
Stock-based compensation		7,265		1,129		3,075	
Adjusted EBITDA	\$	(16,407)	\$	(10,527)	\$	(14,207)	

Copyright 2022. Momentus inc. Not Export Controlled. Any use, reproduction, or distribution without the express consent of Momentus a strictly prohibited when the Company determined they would not be signed and paid.

GAAP to Non-GAAP Reconciliation – SG&A and R&D
A reconciliation of selling, general, and administrative expenses to non-GAAP selling, general, and administrative expenses for

13

A reconciliation of selling, general, and administrative expenses to non-GAAP selling, general, and administrative expenses to
the three months ended December 31, 2021. December 31, 2020, and Sentember 30, 2021, is set forth below:

	Three Months Ended						
in thousands)	December 31, 2021		December 31, 2020		September 30, 2021		
Selling, general, and administrative expenses	\$	13,103	S	4,467	\$	12,057	
Stock-based compensation		5,109		1,050		3,023	
SEC and CFIUS legal expenses		464		-		2,188	
Reduction in SEC and CFIUS legal expenses due to fee disp resolution	oute	(2,551)				_	
Class action litigation legal expenses		797		_		54	
SEC compliance costs		1,073		_			
NSA compliance costs		905		_		882	
Severance and other related expenses1		(13)		110			
Non-GAAP selling, general, administration expenses - Loss contingencies for certain severance agreements were reverse	s d when the Con	7,318	and in case	3,306	-	5,910 ind paid	
Non-GAAP selling, general, administration expenses	-GAAP resear	7,318 pany determine the and developset forth belo	opment	3,306 vould not be expenses f	signed a	nd paid	
Von-GAAP selling, general, administration expenses - Loss contingencies for certain severance agreements were reverse reconciliation of research and development expenses to nor	n-GAAP resear er 30, 2021, is	7,318 pany determine the and developset forth below T	opment w: hree Mo	3,306 rould not be expenses for onths Ende	signed a or the th	nd paid tree month	
ken-GAAP selling, general, administration expenses - Loss contingencies for certain severance agreements were reverse reconciliation of research and development expenses to nor ded December 31, 2021, December 31, 2020, and September December 31, 2021, December 31, 2020, and September 31, 2020, and 32, 32, 32, 32, 32, 32, 32, 32, 32, 32,	n-GAAP resear er 30, 2021, is	7,318 pany determine the and developset forth belo	opment w: hree Mo Decer	3,306 vould not be expenses f	signed a or the th ed Septo	nd paid	
ion-GAAP selling, general, administration expenses Loss contingencies for certain severance agreements were reverse reconciliation of research and development expenses to nor ded December 31, 2021, December 31, 2020, and September in thousandly	n-GAAP resear er 30, 2021, is	7,318 pany determine the and development set forth below T ember 31,	opment w: hree Mo Decer 2	3,306 rould not be expenses fi enths Ende nber 31,	signed a or the th ed Septo	md paid aree months mber 30,	
ion-GAAP selling, general, administration expenses Luos confignencies for cratia severance agreements were reverse reconciliation of reacenth and development expenses to non- ded December 31, 2021, December 31, 2020, and Septembr in thousandly tesearch and development expenses	n-GAAP resear er 30, 2021, is Dec	7,318 pany determine the and developset forth below T ember 31, 2021	opment w: hree Mo Decer 2	3,306 rould not be expenses for onths Ender aber 31, 020	signed a or the th ed Septo	nd paid tree months mber 30, 2021	
Von-GAAP selling, general, administration expenses - Loss contingencies for certain severance agreements were reverse reconcilitation of research and development expenses to nor ided December 31, 2021, December 31, 2020, and September in thousands/	n-GAAP resear er 30, 2021, is Dec	7,318 pany determine the and developset forth below T ember 31, 2021	opment w: hree Mo Decer 2	3,306 would not be expenses for onths Ender aber 31, 020 8,960	signed a or the th ed Septo	nd paid tree months mber 30, 2021	
Ven-GAAP selling, general, administration expenses - Los contingancies for cettain severance agreements were reverse reconciliation of research and development expenses to nor died December 31, 2021, December 31, 2020, and Septembe in thousando) testaarch and development expenses Peopaid Bauch deposit impairment	n-GAAP resear er 30, 2021, is Dec	7,318 pany determine the and develow set forth below T ember 31, 2021 11,574	opment w: hree Mo Decer 2	3,306 would not be expenses for onths Ender aber 31, 020 8,960 1,500	signed a or the th ed Septo	md paid aree months amber 30, 2021 9,047	

1 - Loss contingencies for certain severance agreements were reversed when the Company determined they would not be signed and paid

Copyright 2022. Momentus Inc. Not Export Controlled. Any use, reproduction, or distribution without the express consent of Momentus is strictly prohibited.

GAAP to Non-GAAP Reconciliation – Adj. EBI	TDA

14

Full year adjusted EBITDA A reconciliation of adjusted EBITDA to net loss for the years ended December 31, 2021, and December 31, 2020 is set forth below:

		Year Ended Dece	
		2021	2020
Net Income (Loss)	\$	120,655 \$	(307,021
Income tax expense		2	1
Interest income		(2)	G
Interest expense		14,229	47
Depreciation & amortization		1,092	59
EBITDA		135,975	(305,974
(Decrease) increase in fair value of SAFE notes		(209,291)	267,29
(Decrease) increase in fair value of warrants		(37,330)	3,17
Realized loss on disposal of assets		17	48
SEC settlement		7,000	_
Transaction costs allocated to warrant liability		4,780	-
Investment banking fees related to SAFE financing		175	1,00
Prepaid launch deposit impairment		9,450	1,50
SEC and CFIUS legal expenses		10,038	-
Reduction in SEC and CFIUS legal expenses due to fee dispute resolution		(2,551)	_
Class action litigation legal expenses		852	-
SEC compliance costs		1,073	_
NSA compliance costs		1,835	-
Severance and other related expenses		136	26
Stock-based compensation		18,452	2,77
Adjusted EBITDA	s	(59,388) \$	(29,48

Copyright 2022. Momentus Inc. Not Export Controlled. Any use, reproduction, or distribution without the express consent of Momentus is strictly prohibited.

### GAAP to Non-GAAP Reconciliation – SG&A and R&D

he years ended December 31, 2021 and December 31, 2020, is set forth below:	ing, general, a		uure	Appended to
	,	ear Ended	Decem	iber 31
(in thousands)		2021		2020
Selling, general, and administrative expenses	\$	48,905	\$	11,945
Stock-based compensation		16,110		2,584
SEC and CFIUS legal expenses		10,038		-
Reduction in SEC and CFIUS legal expenses due to fee dispute resolution		(2,551)		-
Class action litigation legal expenses		852		
SEC compliance costs		1,073		-
NSA compliance costs		1,835		_
Severance and other related expenses		63	_	110
Non-GAAP selling, general, administration expenses	\$	21,483	\$	9,251
		expenses for	r the ve	ears ended
December 31, 2021, and December 31, 2020, is set forth below:		ear Ended		ber 31 2020
Accember 31, 2021, and December 31, 2020, is set forth below:		ear Ended	Decem	2020
Accember 31, 2021, and December 31, 2020, is set forth below:	,	ear Ended	Decem	2020 22,718
Accember 31, 2021, and December 31, 2020, is set forth below: (in thousands) Research and development expenses	,	/ear Ended 2021 51,321	Decem	2020 22,718 1,500
	,	/ear Ended 2021 51,321 9,450	Decem	

Copyright 2022 . Momentus Inc. Not Export Controlled. Any use, reproduction, or distribution without the express consent of Momentus is strictly prohibited.